Cargando…

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer

BACKGROUND: Prioritization of breast cancer patients based on the risk of resistance to tamoxifen plays a significant role in personalized therapeutic planning and improving disease course and outcomes. METHODS: In this work, we demonstrate that a genome-wide pathway-centric computational framework...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahem, Sarra M., Epsi, Nusrat J., Coffman, Frederick D., Mitrofanova, Antonina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585053/ https://www.ncbi.nlm.nih.gov/pubmed/33099086 http://dx.doi.org/10.1016/j.ebiom.2020.103047

Ejemplares similares

pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma
por: Epsi, Nusrat J., et al.
Publicado: (2019)

Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
por: Panja, Sukanya, et al.
Publicado: (2021)

Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer
por: Panja, Sukanya, et al.
Publicado: (2018)

Bipotent Progenitors Do Not Require Androgen Receptor for Luminal Specification during Prostate Organogenesis
por: Shibata, Maho, et al.
Publicado: (2020)

Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia
por: Bohannan, Zachary S., et al.
Publicado: (2022)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation
por: Chua, Chee Wai, et al.
Publicado: (2018)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer
por: Yu, Christina Y., et al.
Publicado: (2021)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
por: Li, Guangliang, et al.
Publicado: (2020)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
por: M. Sieuwerts, Anieta, et al.
Publicado: (2020)

Investigating the molecular mechanisms of Tamoxifen on the EMT pathway among patients with breast cancer
por: Mirzaei, Mohammadhossein, et al.
Publicado: (2022)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway
por: Xing, Jilin, et al.
Publicado: (2019)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer
por: Kim, Clara Yuri, et al.
Publicado: (2021)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
por: Li, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s07n1vnp38cpnar1n2pamf3hrf